Skip to content 
Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs. Its veterinary vaccines include monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine. The company also develops vaccines for household animals. In addition, it exports its products to Vietnam, Pakistan, and Egypt. The company serves direct-end customers, including livestock farmers and local governments, as well as domestic distributors and exporting distributors. The company was founded in 2004 and is based in Jilin, China. Zhengye Biotechnology Holding Limited operates as a subsidiary of Securingium Holding Limited. more
| Time Frame | ZYBT | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | 37.33% | 0.91% | 2.13% |
| 1-Month Return | -12.12% | -0.72% | -0.47% |
| 3-Month Return | -52.31% | 2.24% | 1.29% |
| 6-Month Return | -86.38% | 19.1% | 7.71% |
| 1-Year Return | -76.21% | 7.15% | 14.7% |
| 3-Year Return | -78.81% | 16.96% | 67.75% |
| Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 214.07M | 260.27M | 211.65M | 186.36M | 186.36M | [{"date":"2021-12-31","value":82.25,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":81.32,"profit":true},{"date":"2024-12-31","value":71.6,"profit":true},{"date":"2025-12-31","value":71.6,"profit":true}] |
| Cost of Revenue | 88.67M | 106.75M | 81.80M | 95.06M | 95.06M | [{"date":"2021-12-31","value":83.07,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":76.62,"profit":true},{"date":"2024-12-31","value":89.05,"profit":true},{"date":"2025-12-31","value":89.05,"profit":true}] |
| Gross Profit | 125.39M | 153.52M | 129.85M | 91.30M | 91.30M | [{"date":"2021-12-31","value":81.68,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":84.59,"profit":true},{"date":"2024-12-31","value":59.47,"profit":true},{"date":"2025-12-31","value":59.47,"profit":true}] |
| Gross Margin | 58.58% | 58.98% | 61.35% | 48.99% | 48.99% | [{"date":"2021-12-31","value":95.47,"profit":true},{"date":"2022-12-31","value":96.14,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":79.85,"profit":true},{"date":"2025-12-31","value":79.85,"profit":true}] |
| Operating Expenses | 73.01M | 87.69M | 84.87M | 169.18M | 74.86M | [{"date":"2021-12-31","value":43.15,"profit":true},{"date":"2022-12-31","value":51.83,"profit":true},{"date":"2023-12-31","value":50.16,"profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":44.25,"profit":true}] |
| Operating Income | 52.38M | 65.83M | 44.99M | 17.17M | 16.44M | [{"date":"2021-12-31","value":79.57,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":68.33,"profit":true},{"date":"2024-12-31","value":26.08,"profit":true},{"date":"2025-12-31","value":24.97,"profit":true}] |
| Total Non-Operating Income/Expense | (251.00K) | (4.64M) | (5.33M) | (2.78M) | - | [{"date":"2021-12-31","value":-25100000,"profit":false},{"date":"2022-12-31","value":-464500000,"profit":false},{"date":"2023-12-31","value":-533500000,"profit":false},{"date":"2024-12-31","value":-277800000,"profit":false},{"date":"2025-12-31","value":"-","profit":true}] |
| Pre-Tax Income | 53.07M | 63.91M | 43.76M | 14.39M | 14.39M | [{"date":"2021-12-31","value":83.03,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":68.47,"profit":true},{"date":"2024-12-31","value":22.52,"profit":true},{"date":"2025-12-31","value":22.52,"profit":true}] |
| Income Taxes | 6.60M | 8.17M | 6.25M | - | 924.00K | [{"date":"2021-12-31","value":80.75,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":76.52,"profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":11.31,"profit":true}] |
| Income After Taxes | 46.47M | 55.74M | 37.51M | - | - | [{"date":"2021-12-31","value":83.36,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":67.29,"profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Income From Continuous Operations | 46.47M | 55.74M | 37.51M | 13.47M | - | [{"date":"2021-12-31","value":83.36,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":67.29,"profit":true},{"date":"2024-12-31","value":24.16,"profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Net Income | 38.96M | 46.73M | 31.46M | 11.31M | 11.31M | [{"date":"2021-12-31","value":83.36,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":67.31,"profit":true},{"date":"2024-12-31","value":24.2,"profit":true},{"date":"2025-12-31","value":24.2,"profit":true}] |
| EPS (Diluted) | - | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
| ZYBT | |
|---|---|
| Cash Ratio | 0.15 |
| Current Ratio | 1.31 |
| Quick Ratio | 0.88 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| ZYBT | |
|---|---|
| ROA (LTM) | -3.45% |
| ROE (LTM) | -6.38% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| ZYBT | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.29 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.58 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| ZYBT | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 0.31 |
| P/B | 1.12 |
| EV/R | 2.42 |
| EV/Ebitda | 21.76 |
Zhengye Biotechnology Holding Limited Ordinary Shares (ZYBT) share price today is $1.01
Yes, Indians can buy shares of Zhengye Biotechnology Holding Limited Ordinary Shares (ZYBT) on Vested. To buy
Yes, you can purchase fractional shares of Zhengye Biotechnology Holding Limited Ordinary Shares (ZYBT) via the Vested app. You can start investing in Zhengye Biotechnology Holding Limited Ordinary Shares (ZYBT) with a minimum investment of $1.
You can invest in shares of Zhengye Biotechnology Holding Limited Ordinary Shares (ZYBT) via Vested in three simple steps:
The 52-week high price of Zhengye Biotechnology Holding Limited Ordinary Shares (ZYBT) is $14.3. The 52-week low price of Zhengye Biotechnology Holding Limited Ordinary Shares (ZYBT) is $0.72.
The price-to-earnings (P/E) ratio of Zhengye Biotechnology Holding Limited Ordinary Shares (ZYBT) is
The price-to-book (P/B) ratio of Zhengye Biotechnology Holding Limited Ordinary Shares (ZYBT) is 1.12
The dividend yield of Zhengye Biotechnology Holding Limited Ordinary Shares (ZYBT) is 0.00%
The market capitalization of Zhengye Biotechnology Holding Limited Ordinary Shares (ZYBT) is $48.34M
The stock symbol (or ticker) of Zhengye Biotechnology Holding Limited Ordinary Shares is ZYBT
Consider the share price of Zhengye Biotechnology Holding Limited Ordinary Shares as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Zhengye Biotechnology Holding Limited Ordinary Shares has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Zhengye Biotechnology Holding Limited Ordinary Shares shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Zhengye Biotechnology Holding Limited Ordinary Shares stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Zhengye Biotechnology Holding Limited Ordinary Shares and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Zhengye Biotechnology Holding Limited Ordinary Shares stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
